130 - References

References

124 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

1. Leucht S, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-­analysis. Lancet 2012; 379:2063–2071.
2. Murray RM, et al. Should psychiatrists be more cautious about the long-­term prophylactic use of antipsychotics? Br J Psychiatry 2016; 209:361–365.
3. Wunderink L, et al. Recovery in remitted first-­episode psychosis at 7 years of follow-­up of an early dose reduction/discontinuation or maintenance treatment strategy: long-­term follow-­up of a 2-­year randomized clinical trial. JAMA Psychiatry 2013; 70:913–920.
4. Wunderink L, et al. Guided discontinuation versus maintenance treatment in remitted first-­episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007; 68:654–661.
5. Moncrieff J, et al. Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-­group, randomised controlled trial. Lancet Psychiatry 2023; 10:848–859.
6. Omachi Y, et al. Dose reduction/discontinuation of antipsychotic drugs in psychosis; effect on cognition and functional outcomes. Front Psychiatry 2018; 9:447.
7. Moncrieff J. Antipsychotic maintenance treatment: time to rethink? PLoS Med 2015; 12:e1001861.
8. Marston L, et al. Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open 2014; 4:e006135.
9. National Institute for Health and Care Excellence. Borderline personality disorder: recognition and management. Clinical guideline [CG78]. 2009 (last checked April 2022, last accessed January 2024); https://www.nice.org.uk/guidance/CG78.
10. National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [NG97]. 2018 (last checked September 2023, last accessed December 2023); https://www.nice.org.uk/guidance/ng97.
11. Cerovecki A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs 2013; 27:545–572.
12. Chouinard G, et al. Antipsychotic-­induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy. Psychother Psychosom 2017; 86:189–219.
13. Brandt L, et al. Antipsychotic withdrawal symptoms: a systematic review and meta-­analysis. Front Psychiatry 2020; 11:569912.
14. Brandt L, et al. Adverse events after antipsychotic discontinuation: an individual participant data meta-­analysis. Lancet Psychiatry 2022; 9:232–242.
15. Morant N, et  al. Experiences of reduction and discontinuation of antipsychotics: a qualitative investigation within the RADAR trial. EClinicalMedicine 2023; 64:102135.
16. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-­related relapse. Acta Psychiatr Scand 2006; 114:3–13.
17. Lu ML, et al. Metoclopramide-­induced supersensitivity psychosis. Ann Pharmacother 2002; 36:1387–1390.
18. Roy-­Desruisseaux J, et al. Domperidone-­induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia. Ann Pharmacother 2011; 45:e51.
19. Seeman P. Breast is best but taper domperidone when stopping [e-­letter]. Br J Gen Pract 2014; https://bjgp.org/content/ yes-­breast-­best-­taper-­domperidone-­when-­stopping.
20. Horowitz MA, et al. Gradually tapering off antipsychotics: lessons for practice from case studies and neurobiological principles. Curr Opin Psychiatry 2024; 37:320–330.
21. Viguera AC, et  al. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Archives of General Psychiatry 1997; 54:49–55.
22. Bogers JPAM, et al. Risk factors for psychotic relapse after dose reduction or discontinuation of antipsychotics in patients with chronic schizophrenia: a systematic review and meta-­analysis. Schizophr Bull Open 2020; 50:722.
23. Bogers J, et al. Risk factors for psychotic relapse after dose reduction or discontinuation of antipsychotics in patients with chronic schizophrenia. A meta-­analysis of randomized controlled trials. Schizophr Bull 2023; 49:11-­23.
24. Chouinard G, et al. Atypical antipsychotics: CATIE study, drug-­induced movement disorder and resulting iatrogenic psychiatric-­like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 2008; 77:69–77.
25. Howes OD, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012; 69:776–786.
26. Joyce JN. D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period. Synapse 2001; 40:137–144.
27. Quinn R. Comparing rat’s to human’s age: how old is my rat in people years? Nutrition 2005; 21:775–777.
28. Marsden CD. Is tardive dyskinesia a unique disorder? Psychopharmacology Suppl 1985; 2:64–71.
29. Schoretsanitis G, et al. Predictors of lack of relapse after random discontinuation of oral and long-­acting injectable antipsychotics in clinically stabilized patients with schizophrenia: a re-­analysis of individual participant data. Schizophr Bull 2022; 48:296–306.
30. Liu CC, et al. Guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis: a 2-­year randomized controlled trial with a naturalistic cohort. Psychol Med 2023; 53:7078–7086.
31. Lako IM, et al. Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-­analysis. J Clin Psychopharmacol 2013; 33:675–681.
32. Holford N. Pharmacodynamic principles and the time course of delayed and cumulative drug effects. Transl Clin Pharmacol 2018; 26:56–59.
33. Leucht S, et al. Dose–response meta-­analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry 2020; 177:342–353.

Schizophrenia and related psychoses CHAPTER 1 34. Leucht S, et al. Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: a meta-­analysis. JAMA Psychiatry 2021; 78:1238–1248. 35. Horowitz MA, et al. Limitations in research on maintenance treatment for individuals with schizophrenia. JAMA Psychiatry 2022; 79:83–85. 36. Horowitz MA, et al. Tapering antipsychotic treatment. JAMA Psychiatry 2020; 78:125–126. 37. O’Neill JR, et al. Implementing gradual, hyperbolic tapering of long-­acting injectable antipsychotics by prolonging the inter-­dose interval: an in silico modelling study. Ther Adv Psychopharmacol 2023; 13:20451253231198463. 38. O’Neill J, et al. Using in silico methods to determine optimal tapering regimens for decanoate-­based long-­acting injectable psychosis drugs. Ther Adv Psychopharmacol 2024; 14:20451253241272790.